Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 165 versus KERYDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 165 versus KERYDIN.
FULVICIN P/G 165 vs KERYDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by inhibiting spindle formation and mitosis in dermatophytes, leading to inhibition of fungal cell division.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
165 mg orally once daily.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
None Documented
None Documented
Terminal elimination half-life is approximately 9-24 hours; dependent on formulation and absorption rate. Steady-state achieved within 4-5 days.
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Primarily renal excretion of metabolites; <1% excreted unchanged. Biliary/fecal elimination accounts for ~30% of metabolites.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Category C
Category C
Antifungal
Antifungal